<p>4D Molecular Therapeutics, Inc.（纳斯达克代码：FDMT - 获取免费报告）内部人士 Scott Bizily 于 11 月 17 日星期一出售了 1,635 股该公司的股票。股票以平均价格 10.59 美元出售，总价值为 17,314.65 美元。交易后，该内部人士直接持有 3,594 股公司股票，价值为 38,060.46 美元。此次交易使其持股减少了 31.27%。该交易已在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。</p>
<p>Scott Bizily 最近还进行了以下交易：</p>
<ul>
<li>10 月 24 日星期五，Scott Bizily 出售了 2,678 股 4D Molecular Therapeutics 的股票。股票以平均价格 12.00 美元出售，总价值为 32,136.00 美元。</li>
<li>10 月 16 日星期四，Scott Bizily 出售了 1,635 股 4D Molecular Therapeutics 的股票。股票以平均价格 10.17 美元出售，总价值为 16,627.95 美元。</li>
<li>10 月 9 日星期四，Scott Bizily 出售了 2,408 股 4D Molecular Therapeutics 的股票。股票以平均价格 10.00 美元出售，总价值为 24,080.00 美元。</li>
<li>9 月 23 日星期二，Scott Bizily 出售了 2,407 股 4D Molecular Therapeutics 的股票。股票以平均价格 8.00 美元出售，总交易额为 19,256.00 美元。</li>
</ul>
<h2>4D Molecular Therapeutics 股价上涨 7.0%</h2>
<p>在周三的午盘交易中，纳斯达克：FDMT 上涨 0.71 美元，达到 10.80 美元。该股票的交易量为 904,864 股，而其平均交易量为 1,057,282 股。4D Molecular Therapeutics, Inc.的 12 个月最低价为 2.23 美元，最高价为 12.34 美元。该股票的 50 日简单移动平均线为 9.54 美元，200 日简单移动平均线为 6.43 美元。该公司的市值为 6.17 亿美元，市盈率为-2.88，贝塔系数为 2.96。</p>
<p>4D Molecular Therapeutics（纳斯达克代码：FDMT - 获取免费报告）最近于 11 月 10 日星期一公布了季度财报。公司报告本季度每股收益（EPS）为-1.01 美元，超出分析师一致预期的-1.02 美元 0.01 美元。4D Molecular Therapeutics 的净利润率为-174,314.17%，股本回报率为-47.27%。本季度公司收入为 9 万美元，而一致预期为 40 万美元。卖方分析师预测 4D Molecular Therapeutics, Inc.在本财年将发布-2.84 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票分析师最近对 FDMT 股票发表了评论。巴克莱将 4D Molecular Therapeutics 的目标价格从 38.00 美元下调至 33.00 美元，并在 11 月 11 日星期二的报告中对该股票给予了 “超配” 评级。Leerink Partners 重申了 “跑赢大盘” 评级，并在 10 月 31 日星期五的研究报告中将 4D Molecular Therapeutics 的目标价格设定为 17.00 美元。摩根士丹利在 11 月 7 日星期五的研究报告中将 4D Molecular Therapeutics 的评级从 “减持” 上调至 “持平”。加拿大皇家银行在 11 月 11 日星期二的研究报告中将 4D Molecular Therapeutics 的目标价格从 26.00 美元上调至 32.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 4D Molecular Therapeutics 的 “卖出（d-）” 评级。八位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 28.70 美元。</p>
<p><strong>阅读我们关于 FDMT 的最新报告</strong></p>
<h2>4D Molecular Therapeutics 的机构交易</h2>
<p>一些大型投资者最近对 FDMT 的持仓进行了调整。Armistice Capital LLC 在第三季度将其在 4D Molecular Therapeutics 的股份增加了 265.3%。Armistice Capital LLC 现在持有 1,096,000 股公司股票，价值 9,524,000 美元，此前在上个季度又购买了 796,000 股。Wexford Capital LP 在第三季度获得了 4D Molecular Therapeutics 的新股份，价值约为 41,000 美元。Prelude Capital Management LLC 在第三季度将其在 4D Molecular Therapeutics 的持股增加了 11.1%。Prelude Capital Management LLC 现在持有 23,000 股公司股票，价值 200,000 美元，此前在此期间又购买了 2,300 股。Parkman Healthcare Partners LLC 在第三季度购买了 4D Molecular Therapeutics 的新股份，价值约为 1,738,000 美元。最后，Brevan Howard Capital Management LP 在第三季度获得了 4D Molecular Therapeutics 的新股份，价值 143,000 美元。99.27% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 4D Molecular Therapeutics</h2>
<p>（获取免费报告）</p>
<p>4D Molecular Therapeutics, Inc.是一家临床阶段的生物治疗公司，利用其治疗载体进化平台在荷兰和美国开发基因药物。该公司开发了一系列基因药物候选产品，专注于眼科、心脏病学和肺病学三个治疗领域。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 4D Molecular Therapeutics 更好</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>onsemi 对其自身股票下注 60 亿美元</li>
<li>如何从价值投资中获利</li>
<li>HIMS 经历了过山车般的旅程。投资者应该上车吗？</li>
<li>如何使用股票筛选器寻找股票</li>
<li>以这三只反弹冠军强势结束年末</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 4D Molecular Therapeutics 吗？</h2>
<p>在考虑 4D Molecular Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 4D Molecular Therapeutics 并不在名单上。</p>
<p>虽然 4D Molecular Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

FDMT

<p>4D Molecular Therapeutics 的内部人士 Scott Bizily 出售了 1,635 股，交易金额为 17,314.65 美元，减少了 31.27% 的持股比例。该交易在 SEC 文件中披露。公司最近公布了季度财报，略微超出预期，分析师对该股票的评级意见不一。机构投资者已调整在公司的持仓，Armistice Capital 显著增加了其股份</p>

<p>4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the business's stock in a transaction on Monday, November 17th. The stock was sold at an average price of $10.59, for a total value of $17,314.65. Following the transaction, the insider directly owned 3,594 shares of the company's stock, valued at $38,060.46. The trade was a 31.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics, Inc.（纳斯达克代码：FDMT - 获取免费报告）内部人士 Scott Bizily 于 11 月 17 日星期一出售了 1,635 股该公司的股票。股票以平均价格 10.59 美元出售，总价值为 17,314.65 美元。交易后，该内部人士直接持有 3,594 股公司股票，价值为 38,060.46 美元。此次交易使其持股减少了 31.27%。该交易已在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。</p>
</div><p>Scott Bizily also recently made the following trade(s):</p>
<div class="lb-trans"><p>Scott Bizily 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $32,136.00.</li>
<li>On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.17, for a total value of $16,627.95.</li>
<li>On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $24,080.00.</li>
<li>On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total transaction of $19,256.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>10 月 24 日星期五，Scott Bizily 出售了 2,678 股 4D Molecular Therapeutics 的股票。股票以平均价格 12.00 美元出售，总价值为 32,136.00 美元。</li>
<li>10 月 16 日星期四，Scott Bizily 出售了 1,635 股 4D Molecular Therapeutics 的股票。股票以平均价格 10.17 美元出售，总价值为 16,627.95 美元。</li>
<li>10 月 9 日星期四，Scott Bizily 出售了 2,408 股 4D Molecular Therapeutics 的股票。股票以平均价格 10.00 美元出售，总价值为 24,080.00 美元。</li>
<li>9 月 23 日星期二，Scott Bizily 出售了 2,407 股 4D Molecular Therapeutics 的股票。股票以平均价格 8.00 美元出售，总交易额为 19,256.00 美元。</li>
</ul>
</div><h2>4D Molecular Therapeutics Trading Up 7.0%</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 股价上涨 7.0%</h2>
</div><p>NASDAQ:FDMT traded up $0.71 during mid-day trading on Wednesday, hitting $10.80. The stock had a trading volume of 904,864 shares, compared to its average volume of 1,057,282. 4D Molecular Therapeutics, Inc. has a twelve month low of $2.23 and a twelve month high of $12.34. The stock has a 50-day simple moving average of $9.54 and a two-hundred day simple moving average of $6.43. The company has a market capitalization of $617.00 million, a PE ratio of -2.88 and a beta of 2.96.</p>
<div class="lb-trans"><p>在周三的午盘交易中，纳斯达克：FDMT 上涨 0.71 美元，达到 10.80 美元。该股票的交易量为 904,864 股，而其平均交易量为 1,057,282 股。4D Molecular Therapeutics, Inc.的 12 个月最低价为 2.23 美元，最高价为 12.34 美元。该股票的 50 日简单移动平均线为 9.54 美元，200 日简单移动平均线为 6.43 美元。该公司的市值为 6.17 亿美元，市盈率为-2.88，贝塔系数为 2.96。</p>
</div><p>4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million. Sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics（纳斯达克代码：FDMT - 获取免费报告）最近于 11 月 10 日星期一公布了季度财报。公司报告本季度每股收益（EPS）为-1.01 美元，超出分析师一致预期的-1.02 美元 0.01 美元。4D Molecular Therapeutics 的净利润率为-174,314.17%，股本回报率为-47.27%。本季度公司收入为 9 万美元，而一致预期为 40 万美元。卖方分析师预测 4D Molecular Therapeutics, Inc.在本财年将发布-2.84 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities analysts recently commented on FDMT shares. Barclays dropped their target price on 4D Molecular Therapeutics from $38.00 to $33.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, November 11th. Leerink Partners reaffirmed an &#34;outperform&#34; rating and set a $17.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Morgan Stanley raised 4D Molecular Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating in a research report on Friday, November 7th. Royal Bank Of Canada boosted their target price on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $28.70.</p>
<div class="lb-trans"><p>几位股票分析师最近对 FDMT 股票发表了评论。巴克莱将 4D Molecular Therapeutics 的目标价格从 38.00 美元下调至 33.00 美元，并在 11 月 11 日星期二的报告中对该股票给予了 “超配” 评级。Leerink Partners 重申了 “跑赢大盘” 评级，并在 10 月 31 日星期五的研究报告中将 4D Molecular Therapeutics 的目标价格设定为 17.00 美元。摩根士丹利在 11 月 7 日星期五的研究报告中将 4D Molecular Therapeutics 的评级从 “减持” 上调至 “持平”。加拿大皇家银行在 11 月 11 日星期二的研究报告中将 4D Molecular Therapeutics 的目标价格从 26.00 美元上调至 32.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 4D Molecular Therapeutics 的 “卖出（d-）” 评级。八位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 28.70 美元。</p>
</div><p><strong>Read Our Latest Report on FDMT</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 FDMT 的最新报告</strong></p>
</div><h2>Institutional Trading of 4D Molecular Therapeutics</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 的机构交易</h2>
</div><p>A number of large investors have recently made changes to their positions in FDMT. Armistice Capital LLC grew its stake in 4D Molecular Therapeutics by 265.3% during the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company's stock worth $9,524,000 after buying an additional 796,000 shares during the last quarter. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $41,000. Prelude Capital Management LLC boosted its holdings in shares of 4D Molecular Therapeutics by 11.1% in the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company's stock valued at $200,000 after acquiring an additional 2,300 shares during the period. Parkman Healthcare Partners LLC purchased a new position in shares of 4D Molecular Therapeutics during the third quarter worth approximately $1,738,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $143,000. 99.27% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近对 FDMT 的持仓进行了调整。Armistice Capital LLC 在第三季度将其在 4D Molecular Therapeutics 的股份增加了 265.3%。Armistice Capital LLC 现在持有 1,096,000 股公司股票，价值 9,524,000 美元，此前在上个季度又购买了 796,000 股。Wexford Capital LP 在第三季度获得了 4D Molecular Therapeutics 的新股份，价值约为 41,000 美元。Prelude Capital Management LLC 在第三季度将其在 4D Molecular Therapeutics 的持股增加了 11.1%。Prelude Capital Management LLC 现在持有 23,000 股公司股票，价值 200,000 美元，此前在此期间又购买了 2,300 股。Parkman Healthcare Partners LLC 在第三季度购买了 4D Molecular Therapeutics 的新股份，价值约为 1,738,000 美元。最后，Brevan Howard Capital Management LP 在第三季度获得了 4D Molecular Therapeutics 的新股份，价值 143,000 美元。99.27% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About 4D Molecular Therapeutics</h2>
<div class="lb-trans"><h2>关于 4D Molecular Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics, Inc.是一家临床阶段的生物治疗公司，利用其治疗载体进化平台在荷兰和美国开发基因药物。该公司开发了一系列基因药物候选产品，专注于眼科、心脏病学和肺病学三个治疗领域。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than 4D Molecular Therapeutics</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>onsemi Places a $6 Billion Bet on Its Own Stock</li>
<li>How to Profit From Value Investing</li>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>End the Year Strong With These 3 Comeback Champions</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 4D Molecular Therapeutics 更好</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>onsemi 对其自身股票下注 60 亿美元</li>
<li>如何从价值投资中获利</li>
<li>HIMS 经历了过山车般的旅程。投资者应该上车吗？</li>
<li>如何使用股票筛选器寻找股票</li>
<li>以这三只反弹冠军强势结束年末</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 4D Molecular Therapeutics 吗？</h2>
</div><p>Before you consider 4D Molecular Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 4D Molecular Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 4D Molecular Therapeutics 并不在名单上。</p>
</div><p>While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 4D Molecular Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部人士出售：4D Molecular Therapeutics（NASDAQ:FDMT）的内部人士出售了价值 17,314.65 美元的股票